Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical tacrolimus 0.1% after penetrating keratoplasty
jRCTs031180342Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Nov 2017
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial of tacrolimus in keratoplasty rejection (CGR) and penetrating keratoplasty (PKP) (2 arms), sponsored by Senju Pharmaceutical Co., Ltd. Primary endpoint: Graft rejection rate at week 52. Started Nov 2017; status: completed.
02
Drugs
tacrolimus
03
Conditions
keratoplasty rejection (CGR)penetrating keratoplasty (PKP)
Beyond the preview
Go deeper on jRCTs031180342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180342.